期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 16, 期 12, 页码 1235-1245出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2016.1244008
关键词
Mesothelioma; angiogenesis; vascular endothelial growth factor; tumour microenvironment; anti-angiogenic agents
类别
资金
- Lyall Watt's Mesothelioma grant - Cancer Council Victoria and Victorian Cancer Agency
- Victorian Government, Australia
- NHMRC [APP1074035, 1059844]
Introduction: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated with a poor prognosis. Areas covered: MMs induce a strong inflammatory response that is also associated with neoangiogenesis and activation of proangiogenic factors. Given this, several anti-angiogenic agents have been trialled in a variety of malignancies including mesothelioma. Herein we summarise the role of angiogenesis in MM and the current available data targeting these pathways. Expert commentary: The addition of bevacizumab to cisplatin/pemetrexed chemotherapy is currently a therapeutic option with a proven 2.7 month overall survival benefit in fit patients less than 75. Other antiangiogenics such as nintedinib show early promise, although the Phase III trial results are eagerly awaited before this therapy enters treatment paradigms. Beyond this, it is likely that combinations of antiangiogenics with immunotherapies will be investigated in future studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据